Acute Myeloid Leukemia (AML) grows at lightning speed and demands urgent, personalised treatment, here’s why early diagnosis ...

Through bone marrow aspiration, they identified 14 cases of acute lymphoblastic leukemia (ALL), one case of chronic lymphoblastic leukemia, six cases of acute myeloid leukemia (AML), and one case of ...

"Vascular surgeon here. A sudden onset of pain in your calf when you walk should NEVER be ignored. It could be a clot in an artery or vein that must be addressed immediately." ...

Could a legendary tomb curse become a medical miracle? Scientists may have reengineered Aspergillus flavus, linked to King ...

Regarding the pediatric population, mold-active antifungal prophylaxis is recommended for pediatric patients at high risk of IFD, including a subgroup of children with ALL.

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in myelodysplastic syndrome. Read more here.

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...